Cipralisant

Cipralisant (GT-2331) is an orally active, low-toxicity, potent, selective, high affinity histamine H3 receptor full antagonist in vivo, and an agonist in vitro, with a pKi of 9.9 for histamine H3 receptor and a Ki of 0.47 nM for rat histamine H3 receptor. Cipralisant has the potential for attention-deficit hyperactivity disorder research[1][2][3][4]. Cipralisant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

CAS Number

[213027-19-1]

Product Name Alternative

GT-2331

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Histamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Cipralisant.html

Purity

99.26

Solubility

DMSO : 200 mg/mL (ultrasonic)

Smiles

CC(C)(C)CCC#C[C@H]1[C@H](C2=CN=CN2)C1

Molecular Formula

C14H20N2

Molecular Weight

216.32

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Raddatz R, et al. Histamine H3 antagonists for treatment of cognitive deficits in CNS diseases. Curr Top Med Chem. 2010;10 (2) :153-169.|[2]Fox GB, et al. Effects of histamine H (3) receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup. Behav Brain Res. 2002;131 (1-2) :151-161.|[3]Ito S, et al. Detailed pharmacological characterization of GT-2331 for the rat histamine H3 receptor. Eur J Pharmacol. 2006;529 (1-3) :40-46.|[4]Tedford CE, et al. High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models. Eur J Pharmacol. 1998;351 (3) :307-311.